Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 14:14:1399574.
doi: 10.3389/fonc.2024.1399574. eCollection 2024.

Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis

Mengzhang Xie #  1   2 , Qi Huang #  3 , Taojun Gong  1   2 , Yitian Wang  1   2 , Zhuangzhuang Li  1   2 , Minxun Lu  1   2 , Yi Luo  1   2 , Li Min  1   2 , Yong Zhou  1   2 , Chongqi Tu  1   2
Affiliations

Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis

Mengzhang Xie et al. Front Oncol. .

Abstract

Introduction: Desmoid fibromatosis is an aggressive fibroblastic neoplasm with a high propensity for local recurrence. Targeted therapy for Desmoid fibromatosis represents a novel avenue in systemic treatment. Anlotinib, a novel multitargeted angiogenesis inhibitor, represents a novel approach for targeted therapy. Therefore, this study aims to assess the efficacy and safety of anlotinib in patients with Desmoid fibromatosis.

Methods: We retrospectively gathered the clinical medical records of Desmoid fibromatosis patients who underwent anlotinib treatment between June 2019 and November 2023 at our center. Anlotinib was initiated at a daily dose of 12 mg and adjusted based on drug-related toxicity. Tumor response was evaluated using the Response Evaluation Criteria in Solid Tumors 1.1 criteria. Progression-free survival served as the primary endpoint and was analyzed utilizing the Kaplan-Meier method.

Results: In total, sixty-six consecutive patients were enrolled. No patients achieved a complete response; however, fourteen patients (21.21%) exhibited a partial response, while forty-six patients (70%) experienced disease stability. Progressive disease was observed in 6 patients (9.10%), and the progression-free survival rates at 12 and 36months were 89.71% and 82.81%, respectively. The disease control rate was 90.91%, while the objective response rate was 21.21%.

Conclusion: Anlotinib proves effective in managing recurrent and symptomatic patients with Desmoid fibromatosis. However, the toxicity profile of anlotinib presents a higher risk of Hand-Foot Skin Reaction and hypertension. Therefore, given that 41.67% of patients were subjected to dose adjustments associated with the initial dose of 12 mg, implementing dosage reductions may help balance efficacy with side effects.

Keywords: anlotinib; desmoid fibromatosis; dosage adjustments; targeted therapy; tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Kaplan-Meier curve demonstrating progression-free survival in all patients.
Figure 2
Figure 2
Kaplan-Meier curve demonstrating progression-free survival in three initial dose.
Figure 3
Figure 3
Change from baseline.
Figure 4
Figure 4
A 28-year-old patient with 6 months of anlotinib.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. G. Desmoid Tumor Working . The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. (2020) 127:96–107. doi: 10.1016/j.ejca.2019.11.013 - DOI - PubMed
    1. Penel N, Coindre JM, Bonvalot S, Italiano A, Neuville A, Le Cesne A, et al. . Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. Eur J Cancer. (2016) 58:90–6. doi: 10.1016/j.ejca.2016.02.008 - DOI - PubMed
    1. Kasper B, Ströbel P, Hohenberger P. Desmoid tumors: clinical features and treatment options for advanced disease. oncologist. (2011) 16:682–93. doi: 10.1634/theoncologist.2010-0281 - DOI - PMC - PubMed
    1. Gounder MM. Notch inhibition in desmoids: "Sure it works in practice, but does it work in theory? Cancer. (2015) 121:3933–7. doi: 10.1002/cncr.29562 - DOI - PubMed
    1. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. editors. WHO Classification of Tumours of Soft Tissue and Bone. Pathology and Genetics of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC Press. (2013).

LinkOut - more resources